Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6321248 | 0.93 | RORC (0.57) | RORC | |
| SCHEMBL5758686 | 0.83 | RORC (0.65) | RORC | |
| SCHEMBL4301678 | 0.79 | FNTA (0.71) | RORC | |
| SCHEMBL6010415 | 0.79 | RORC (0.58) | RORC | |
| SCHEMBL4302818 | 0.78 | FNTA (0.72) | RORC | |
| SCHEMBL6171534 | 0.78 | RORC (0.60) | RORC | |
| SCHEMBL6170022 | 0.77 | RORC (0.54) | RORC | |
| SCHEMBL6174296 | 0.76 | RORC (0.51) | RORC | |
| SCHEMBL13178093 | 0.76 | FNTA (0.55) | RORC | |
| SCHEMBL6171298 | 0.76 | RORC (0.57) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844357-B2 | Substituted quinolin-2-one derivatives useful as antiproliferative agents | PFIZER INC. (US) | 2005-01-18 | — | — | US | claimed |
| US-20030166675-A1 | Substituted quinolin-2-one derivatives useful as antiproliferative agents | PFIZER INC. | 2003-09-04 | — | — | US | claimed |
| US-8232402-B2 | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications | LINK MEDICINE CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| WO-2009151683-A2 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | LINK MEDICINE CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| US-6844357-B2 | Substituted quinolin-2-one derivatives useful as antiproliferative agents | PFIZER INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20030166675-A1 | Substituted quinolin-2-one derivatives useful as antiproliferative agents | PFIZER INC. | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | PANK1, PANK3, PANK2 | RORC 1620/4885 |
| US-20030166675-A1 | Substituted quinolin-2-one derivatives useful as antiproliferative agents | CCNA1, NRAS, CCNA2 | RORC 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.